Zevra Therapeutics (ZVRA) Income towards Parent Company: 2014-2025
Historic Income towards Parent Company for Zevra Therapeutics (ZVRA) over the last 11 years, with Sep 2025 value amounting to -$544,000.
- Zevra Therapeutics' Income towards Parent Company rose 98.36% to -$544,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 139.40%. This contributed to the annual value of -$105.5 million for FY2024, which is 129.13% down from last year.
- Zevra Therapeutics' Income towards Parent Company amounted to -$544,000 in Q3 2025, which was down 100.73% from $74.7 million recorded in Q2 2025.
- Zevra Therapeutics' Income towards Parent Company's 5-year high stood at $74.7 million during Q2 2025, with a 5-year trough of -$35.7 million in Q4 2024.
- Over the past 3 years, Zevra Therapeutics' median Income towards Parent Company value was -$13.2 million (recorded in 2023), while the average stood at -$7.3 million.
- Per our database at Business Quant, Zevra Therapeutics' Income towards Parent Company skyrocketed by 622.12% in 2021 and then tumbled by 674.39% in 2024.
- Zevra Therapeutics' Income towards Parent Company (Quarterly) stood at -$2.7 million in 2021, then skyrocketed by 368.41% to $7.3 million in 2022, then slumped by 374.18% to -$19.9 million in 2023, then slumped by 79.67% to -$35.7 million in 2024, then spiked by 98.36% to -$544,000 in 2025.
- Its last three reported values are -$544,000 in Q3 2025, $74.7 million for Q2 2025, and -$3.1 million during Q1 2025.